Company: PFSA
Filing Date: 2025-05-13
Form Type: S-4/A
Source: 0001213900-25-042224
Chunk: 70

Company: Profusa, Inc.
Filing Date: 2025-05-13
Form: S-4/A
Chunk 70
---
 other matters, in evaluating the Business Combination, and in recommending to stockholders that they approve the Business Combination. NorthView Holders should take these interests into account in deciding whether to approve the Business Combination. These interests include, among other things: •The Sponsor beneficially owns 4,743,750 founder shares, which shares would become worthless if NorthView does not complete a business combination within the applicable time period, as such NorthView Initial Stockholders have waived any right to redemption with respect to these shares. The Initial Stockholders paid an aggregate of $25,000 (or $0.005 per share) for 5,175,000 founder shares, 862,500 of which it subsequently forfeited for no consideration. Sponsor subsequently received an additional 431,250 founder shares through a 1.1 -for-1stock dividend. Such shares have an aggregate market value of approximately $[•] based on the closing price of NorthView Common Stock of $[•] on [•], the Record Date for the special meeting of stockholders. •The Sponsor also beneficially owns 5,162,500 private placement warrants, for which it paid $5,162,500 and which will expire and be worthless if NorthView does not complete a business combination within the applicable time period. •NorthView’s officers and directors have an aggregate of $560,833 invested in the Sponsor, which will be lost in the event that the Business Combination is not approved and concluded. •Certain of NorthView’s officers and directors have invested an aggregate of $115,000 into Profusa’s Bridge Notes, which will be converted into shares of Profusa and exchanged for shares of New Profusa Common Stock in connection with the Merger. •NorthView’s directors will not receive reimbursement for any out -of-pocketexpenses incurred by them on NorthView’s behalf incident to identifying, investigating and consummating a business combination, unless a business combination is consummated. As of the date of this proxy statement/prospectus, such out -of-pocketexpenses are approximately $22,650. 7 •Up to an aggregate amount of $2,500,000 of any amounts outstanding under any working capital loans made by Sponsor or any of its affiliates to NorthView may be converted into warrants to purchase New Profusa Common Stock at a price of $1.00 per warrant at the option of the lender. As of the date of this proxy statement/prospectus there were no amounts outstanding under such working capital loans, however, the